The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...

Initially approved in 2012, linaclotide is already indicated for treating chronic idiopathic constipation and IBS-C in adults ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.

The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...

The FDA has updated the label indication for linaclotide capsules for the treatment of irritable bowel syndrome with ...

The FDA has approved linaclotide (Linzess) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation, according to a Nov. 5 news release. Linzess is the first ...

The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older. Previously, ...

B. Longum is known as a “good bacteria” that helps break down food and absorb nutrients, which can help ease digestive ...

The recommended dosage for pediatric patients seven years and older with IBS-C is 145 mcg orally once daily, the FDA said.

Rifaximin is as effective as the low-FODMAP diet in managing irritable bowel syndrome and offers quicker symptom relief and ...

Many of the cases of colon cancer present early symptoms similar to those of IBS, or irritable bowel syndrome, since both ...